Adverse Health Effects Associated with Long-term Exposure to Fine Particulate Matter at Levels below 12 µg/m3 by Djedouboum, Karbet
Georgia State University 
ScholarWorks @ Georgia State University 
Public Health Theses School of Public Health 
5-17-2019 
Adverse Health Effects Associated with Long-term Exposure to 
Fine Particulate Matter at Levels below 12 µg/m3 
Karbet Djedouboum 
Georgia State University 
Follow this and additional works at: https://scholarworks.gsu.edu/iph_theses 
Recommended Citation 
Djedouboum, Karbet, "Adverse Health Effects Associated with Long-term Exposure to Fine Particulate 
Matter at Levels below 12 µg/m3." Thesis, Georgia State University, 2019. 
https://scholarworks.gsu.edu/iph_theses/646 
This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia 
State University. It has been accepted for inclusion in Public Health Theses by an authorized administrator of 
ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu. 
ABSTRACT 
Background: Ambient PM2.5 was ranked the eighth leading risk for mortality in 2017, with a 
total of 2.94 million associated deaths globally. Numerous studies have reported associations 
between long-term exposure to PM2.5 and adverse health effects across a broad range of PM2.5 
concentrations.  However, there is little research on the effect of concentrations below the 
annual PM2.5 National Ambient Air Quality Standards (NAAQS) of 12 µg/m3.  
Objective: Our objective was to assess the association between the levels of ambient PM2.5 
below NAAQS and chronic obstructive pulmonary disease (COPD), asthma, myocardial 
infraction (MI) as captured by hospital admissions; emergency department visits; and mortality. 
Methods: We conducted a cross-sectional study on 2014 data from 265 counties of 27 States of 
the United States (US) retrieved from the Environmental Public Health Tracking Network 
(EPHTN) of the Centers for Disease Control and Prevention (CDC). We used linear and multiple 
linear regression models to assess the association using SAS software.  
Results: At levels below 12 µg/m3, controlling for heat index, a 1-unit change in annual PM2.5 
concentrations was linked with an increase of 2.97 (95%CI: 1.32, 6.69)-unit in COPD 
hospitalizations, a decrease of 0.95 (95%CI: 0.90, 0.99)-unit in COPD EDV, an increase of 2.75 
(95%CI: 1.21, 6.23)-unit in asthma hospitalizations, and an increase of 2.83 (95%CI: 1.34, 5.93)-
unit in asthma EDV. Additionally, long-term exposure to PM2.5 was still associated with some 
outcomes when concentrations were gradually lowered to level below a 9 µg/m3 threshold. 
Conclusion: Our results showed the association between long-term exposure to PM2.5 and 
COPD, asthma, and MI for PM2.5 levels below 12.0 µg/m3. Our findings provide evidence of 
increase health risk below current regulatory standards.   
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Particulate matter (PM) is a complex mixture of liquid droplets or solids particles 
suspended in the air (Wilson et al., 2002). PM originate from different sources, the naturally 
occurring and the anthropogenic. The natural sources are dust clouds from wind storms, salt 
evaporation, smoke and ash from raging forest fires, and volcanic eruptions. The anthropogenic 
sources include stationary sources and mobile contributions. The stationary sources are 
residential heating, chemical plants, electrical plants, factories, manufacturing complexes, oils 
refineries, and incinerators. Mobile sources are cars, buses, off-road equipment, airplanes, 
ships, and trains (Friis, 2012). PM sources are also classified based on composition; a silicon 
factor is classified as soil and crustal material, a lead factor as motor vehicle exhaust, a 
selenium factor representing coal combustion sources, a vanadium factor for fuel oil 
combustion, chlorine factor for salt, and other selected metals such as nickel, zinc, or 
manganese (Laden et al., 2000). Source apportionment methods help to assess the source 
mostly associated with mortality (USEPA, 2019). PM10 are inhalable particles with diameters of 
10 µm and smaller. PM2.5 pollutants include the fine (aerodynamic diameter of less than2.5 µm) 
and the ultrafine (aerodynamic diameter of less than 0.1 µm) (Friis, 2012).  
PM2.5 particles can bypass the body’s normal defensive system and be inhaled more 
deeply into the respiratory tract, some reaching the alveoli (Squadrito et al., 2001). PM2.5 have 
oxidative potential and can interact with macrophages and epithelial cells through reduction-
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oxidation reactions. When they enter blood circulation, they create inflammation, oxidative 
stress and alter immunity with susceptibility to infection (Cachon et al., 2014; Riva et al., 2011). 
PM2.5 disturb the oxidative stress and the inflammation system; that mechanism may result in 
atheroma plaque progression and rupture, endothelial dysfunction with vasoconstriction, 
impaired fibrinolysis and platelet hyperreactivity leading to thrombotic events, and 
arrhythmogenesis (Mills et al., 2009). 
Ambient PM2.5 was ranked as the eighth leading risk for mortality in 2017, with a total of 
2.94 million associated deaths globally (Kyu et al., 2018).  Correia et al. (2013) have 
demonstrated, in a 7-year study in the US, that a reduction of 10 µg/m3 in the concentration of 
PM2.5 was associated with an extension by 0.35 years of the life expectancy.   
In the United States, the monitoring of PM2.5 is part of the mandate of the United States 
Environmental Protection Agency (USEPA) as defined by the Clean Air Act (CAA) established in 
1970. USEPA sets the National Ambient Air Quality Standards (NAAQS) (USEPA, 2017). The CAA 
went through major revisions in 1977 and 1990. NAAQS are set for six following "criteria" 
pollutants in the outdoor air: particulate matter, ozone, sulfur dioxide, nitrogen dioxide, carbon 
monoxide, and lead. The CAA requires USEPA to review the standards of “criteria” pollutants 
through rigorous risk assessment every five years (USEPA, 2017). The NAAQS for PM2.5 is 
defined to primary and secondary. The primary PM2.5 standards are determined to protect the 
human health effects, including the health of "sensitive" populations such as asthmatics, 
children, and the elderly; whereas the role of secondary PM2.5 standards is for welfare 
protection, including protection against decreased visibility, damage to animals, crops, 
vegetation, and buildings. (USEPA, 2016a; USEPA, 2016b).  
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The 24-hour standard and the annual standard are considered for PM2.5 based 
respectively on their short-term (hours up to one month) or long-term (one month to years) 
adverse health effects ( USEPA, 2016a; USEPA, 2016b). In the United States, the annual 
geometric mean standard of PM was established to 75 µg/m3 in 1971 (NAPCA, 1969). The 
annual PM2.5 standard was lowered to 12.0 µg/m3 in 2012 (USEPA, 2016a; USEPA, 2016b). The 
review of the annual PM2.5 standard is evidence-based and required by the C.A.A.; it aims to 
provide increased public health protection (USEPA, 2018a).  
Long-term exposure to PM2.5 has been reported in many reviews and meta-analyses to 
be associated with all-cause mortality (Vodonos, Awad, & Schwartz, 2018; Newby et al., 2014; 
Hart et al., 2015). Annual exposure to PM2.5 is associated with incidence and exacerbation of 
asthma and chronic obstructive pulmonary disease (COPD) (Requia et al., 2018), risk of type 2 
diabetes mellitus (Weinmayr et al., 2015; Weinmayr et al., 2016), risk or death for 
cardiovascular diseases (Ostro et al., 2008; Cesaroni et al., 2014; Shah et al., 2013; Brook et al., 
2010), and risk of lung cancer (Hamra et al., 2014). In the United States, the reduction efforts to 
change the annual PM2.5 standard between 2007 and 2020 was estimated to be associated with 
1,000 avoided additional premature deaths for adults, $53 to $350 million in additional costs, 
and $3.7 to $9 billion of net benefits (Lepeule et al., 2012; USEPA, 2012). 
1.2 Gap and Purpose of Study        
The annual average concentration of PM2.5 was set to 12.0 µg/m3 in 2012 by the USEPA 
as the level to ensure adequate public health protection. Considerable epidemiological studies 
about the association between long-term exposure to PM2.5 and the health effects have 
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covered a range of PM2.5 levels spanning all concentrations. Little research is done to know 
whether the levels of PM2.5  below USEPA standard are protective of public health (Di et al., 
2017). That knowledge would inform future revisions of the NAAQS. We hypothesized that the 
annual exposure to PM2.5 concentrations below the USEPA standard was associated with 
adverse health outcomes such as COPD, asthma, and myocardial infarction (MI).  
The objective of this study is to assess the association between the levels of ambient 
PM2.5 below NAAQS and COPD, asthma, MI as captured by hospital admissions; emergency 
department visits; and mortality. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
We have searched the literature for previous works that indicated the association 
between long-term exposure to PM2.5 and adverse health outcomes. Furthermore, we looked 
for published documents that focused on that relationship when the annual concentrations of 
PM2.5 were at levels below the NAAQS. We have used several conclusions from meta-analyses, 
systematic reviews, and expert panels to support our review.  
2.1 Long-term PM2.5 exposure and all-cause mortality 
The Harvard Six Cities Study, an eight-year cohort study, conducted in six eastern U.S. 
cities showed that a 10 μg/m3 increase in PM2.5 was strongly associated with 1.5% (95%CI: 1.1, 
1.9) increment in total daily mortality, with larger increase in COPD death (3.3%) and ischemic 
heart disease (2.1%) when they controlled for weather (Schwartz et al., 1996). When, weather 
was not controlled for, they found that a 10 μg/m3 increase in PM2.5 was also strongly 
associated with 1.3% (95%CI: 1.0, 1.7) increment in total daily mortality.  An extended follow-up 
for an additional 11 years of the same study showed that an increase in PM2.5 was associated 
with a rise of 14% (95%CI: 7, 22) in risk of all-cause mortality (Lepeule et al. 2012). Additionally, 
the American Cancer Society Study conducted on 552,138 adults who resided in 151 
metropolitan areas showed that exposure to fine particulate matter was associated with all-
cause mortality; the adjusted risk ratio for most polluted areas with the least polluted areas 
was 1.17 (95%CI: 1.09, 1.26) (Pope et al., 1995). Moreover, a follow-up of the Italian cohort of 
1,265,058 subjects provided evidence that long-term exposure to PM2.5 is linked with all-cause 
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mortality (Cesaroni et al., 2014).  Also, Morgan et al. (2003) have found in their study, in Sydney 
metropolitan area, that exposure to low levels of PM2.5 was associated with all-cause 
mortality, including all cardiovascular mortality and all respiratory mortality.  Furthermore, 
Crouse et al. (2012), have found in their analysis of a Canadian cohort of 2.1 million adults that 
long-term exposure to PM2.5 was associated with non-accidental mortality (HR= 1.15, 95%CI: 
1.13, 1.16). Additionally, the follow-up of the cohort of all 60,925,443 Medicare beneficiaries in 
the US from 2000 to 2012 showed 7.3% (95%CI: 7.1, 7.5) increase in all-cause mortality for a 10 
µg/m3 increase in long-term exposure to PM2.5 (Di et al., 2017); that association is 13.6% (95% 
CI, 13.1, 14.1) stronger when the analysis was restricted to an exposure below 12µg/m3 (Di et 
al., 2017). Finally, a cohort from 2000 to 2013 of Medicaid and Medicare beneficiaries above 65 
years old in the Northeast and mid-Atlantic region states showed that more Medicaid 
population would die earlier if exposed to PM2.5 at 12 µg/m3 compared to those exposed to an 
annual average of 7.5 µg/m3 (Schwartz et al., 2018). However, Vodonos, Awad, & Schwartz 
(2018) found recently in their meta-regression that long-term exposure to PM2.5 was associated 
with premature mortality and that the mortality effect is more important below 10 μg/m3 and 
above 20 μg/m3. That difference may be explained by the lack of uniformity in the methods 
used for the different studies included in their review.  
2.2 Long-term PM2.5 exposure and COPD 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as a 
preventable and treatable disease with some significant extrapulmonary effects that may 
contribute to the severity in individual patients (Rabe et al., 2007). The pulmonary component 
of COPD is characterized by airflow limitation that is not fully reversible. The airflow limitation is 
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usually progressive and associated with an abnormal inflammatory response of the lung to 
noxious particles or gases (Rabe et al., 2007). 
Recent studies showed the relationship between long-term exposure to PM2.5 and 
COPD. For instance, Yin et al. (2017), in a cohort study of 189,793 men of 40 years old and older 
in China have indicated that, adjusted for rurality, region and years of education, long-term 
exposure to PM2.5 was associated with COPD mortality (HR=1.12, 95%CI: 1.10, 1.13). Their 
results contrast with what Atkinson et al. (2015) have found in their cohort of 812 063 patients 
in the UK. Atkinson et al. (2015) observed inconclusive results for the association between long-
term PM2.5 exposure and COPD when controlling for covariates such as age, sex, smoking, body 
mass index and area-level (HR of 1.05, 95% CI: 0.98, 1.13).  
2.3 Long term PM2.5 exposure and Asthma  
Asthma is a chronic disorder of the airways that is complex and characterized by 
variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an 
underlying inflammation (NHLBI, 1997). The most common symptoms presented by asthma 
patients are wheezing, cough, chest tightness, and dyspnea; the physical examination can help 
determine the severity of asthma exacerbation (Patadia, Murrill & Corey, 2014).  
Various studies showed the association between annual exposure to PM2.5 and asthma. 
Tétreault et al. (2016) followed in a cohort of 1,183,865 children in Canada and found that, 
after controlling for year of birth, sex and material and social deprivation, exposure to PM2.5 
was associated with asthma (HR of 1.33, 95%CI:1.31, 1.34). Nishimura et al. (2013) have 
determined, in a retrospective case-control of 948 children aged between 8−21 years old in the 
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US, that first year of life exposure to PM2.5 was associated with asthma (OR,1.2, 95%CI: 0.6, 
2.3). Similarly, Gehring et al. (2010), in the Netherlands, have observed in their follow-up of 
3,863 children, from their date of birth to age 8, that PM2.5 levels were linked with an increase 
in the incidence of asthma (OR,1.28, 95%CI: 1.10, 1.49), prevalence of asthma (OR, 1.26; 95% 
CI: 1.04, 1.51), and prevalence of asthma symptoms (OR, 1.15; 95% CI: 1.02, 1.28). The US 
cohort study conducted on 50,884 women indicated that exposure to PM2.5 increases the 
incidence of asthma (Young et al., 2014). In contrast, ESCAPE cohort study, that assessed the 
liaison between annual exposure to PM2.5 and asthma in 23,704 adults in 6 countries and more 
than 20 different cities across Europe, did not show a significant association (Jacquemin et al., 
2015). That observation may be due to the methodology difference between non-
homogeneous cohorts.   
2.4 Long-term PM2.5 exposure and cardiovascular diseases 
The association between long-term exposure to PM2.5 and the risk and mortality for 
cardiovascular diseases is extensively reported in the literature. The American Heart 
Association (AHA) stated, in their updated scientific statement from 2010, that long-term 
exposure to PM2.5 is positively associated with cardiovascular disease mortality (Brook et al., 
2010). A similar observation was done by Liu et al. (2018) in their risk-meta-analysis. Newby et 
al. (2014) have shown the European expert position paper indicating that long-term exposure 
to PM2.5 is associated with various cardiovascular outcomes such as coronary artery disease, 
heart failure, and cerebrovascular disease. Moreover, Duan et al. (2018) have found, among 
1188 women in the Study of Women's Health Across the Nation (SWAN), that long-term 
exposure to PM2.5 may contribute to the increase in atherosclerosis in the post-menopausal 
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period. Also, To et al. (2015) have indicated, in their 30-year longitudinal cohort study, that the 
increase in the prevalence of congestive heart failure, ischemic heart disease, and stroke was 
associated with elevated PM2.5 exposure. Furthermore, Gan et al. (2010) have observed, in their 
cohort study, that the long-term exposure to PM2.5 was linked to a rise in coronary heart 
disease hospitalization and mortality after adjusting for the covariates. Finally, Fu et al. (2018) 
have obtained an association between PM2.5 exposure and risk and mortality for stroke 
(respectively 1.14, 95% CI 1.08, 1.21 and 1.15, 95% CI 1.07, 1.24). 
2.5 Long-term PM2.5 exposure and diabetes 
Various studies concluded on the relationship between long-term exposure to PM2.5 and 
risk for diabetes. A recent cross-sectional and ecological study conducted in Italy by Orioli et al. 
(2018) found that each 10μg/m3 increment of PM2.5 concentration was linked to the odds ratio 
of 1.04 (95% CI 1.02, 1.07) for diabetes. Similarly, Weinmayr et al. (2015) have demonstrated in 
a cohort of 3607 individuals in Germany that long-term exposure to PM2.5 increases the type 2 
diabetes in the general population. Furthermore, Hansen et al. (2016) have found, in the cohort 
of 28,731 female nurses in Denmark, that PM2.5 may be the most associated with diabetes 
development among women, and non-smokers. However, Janghorbani, Momeni & Mansourian 
(2014) have demonstrated in their review on air pollution and the risk of diabetes that the 
association between long-term exposure to PM2.5 and diabetes was weak. 
2.6 Long-term PM2.5 exposure and lung cancer 
Several authors have demonstrated the association between chronic exposure to PM2.5 
and the risk for lung cancer. Chen et al. (2015) have shown, in their meta-analysis, that long-
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term exposure to fine particulate matter (1.11, 95% CI: 1.00, 1.22) was significantly associated 
with risk of lung cancer. The same observation was done by Hamra et al. (2014). They found, in 
their meta-analysis, that lung cancer was associated (1.09, 95% CI: 1.04, 1.14) with long-term 
exposure to PM2.5. Similarly, Lepeule et al. (2012) in the extended follow-up of the Harvard Six 
Cities study, found that a 10 µg/m3 increment in long-term exposure to PM2.5 was associated 
with 37% (95% CI: 7, 75) rise in lung-cancer mortality.  
2.7 Long-term PM2.5 exposure and neurologic diseases 
Studies to date reported the risk of neurologic diseases associated with long-term 
exposure to PM2.5. Kioumourtzoglou et al. (2015) have followed approximatively 9.8 million 
subjects and observed significant associations between long-term exposure to PM2.5 and first 
admission for dementia, Alzheimer’s, or Parkinson’s diseases. Moreover, Fu et al. (2018) have 
indicated, in their review, a significant association between PM2.5 exposure and risk for 
dementia (1.16, 95% CI 1.07, 1.26), for Alzheimer's disease (3.26, 95% 0.84, 12.74), for Autism 
Spectrum Disorder (ASD) (1.68, 95% CI 1.20, 2.34), and for Parkinson's disease (1.34, 95% CI 
1.04, 1.73). 
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CHAPTER III 
MANUSCRIPT 
Introduction 
The World Health Organization (WHO) estimates that environmental factors account for 
23% of global death (Prüss-Üstün et al., 2016). Ambient particulate matter with an aerodynamic 
diameter below 2.5 µg (PM2.5) was ranked eighth mortality risk factor in 2017 and made a total 
of 2.94 million deaths globally (Kyu et al., 2018).  A study in the US has shown that a reduction 
of 10 µg/m3 in the concentration of PM2.5 was associated with the extension of life expectancy 
by 0.35 year (Correia et al., 2013). 
Long-term exposure to PM2.5 was reported in many reviews and meta-analyses to be 
associated with all-cause mortality (Newby et al., 2014; Hart et al., 2015; Vodonos, Awad, & 
Schwartz, 2018). It is more associated with all-cause mortality than short-term exposure to 
PM2.5 (Brook et al., 2010). Additionally, long-term exposure to PM2.5 is associated with risk of 
asthma and chronic obstructive pulmonary disease (COPD) (Requia et al., 2018), risk of type 2 
diabetes mellitus (Weinmayr et al., 2015; Weinmayr et al., 2016), risk or death for 
cardiovascular diseases (Shah et al., 2013; Cesaroni et al., 2014) and risk of lung cancer (Hamra 
et al., 2014).  
In the United States (US), the monitoring of PM2.5 is part of the mandate of the United 
States Environmental Protection Agency (USEPA), as defined by the Clean Air Act (CAA). USEPA 
sets the National Ambient Air Quality Standards (NAAQS) (USEPA, 2016). The NAAQS for the 
annual PM2.5 standard was set to 12.0 µg/m3 in 2012, reference level below which there may be 
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public health protection.  (USEPA, 2009; USEPA, 2016a, USEPA, 2016b). The United States (US) 
has made tremendous advancements in reducing the level of air pollution in general, including 
the level of annual PM2.5 (USEPA, 2018b).  
Considerable epidemiological studies about the relationship between long-term 
exposure to PM2.5 and health effects have covered the whole levels of PM2.5, whether they 
were below or above the NAAQS (Vodonos, Awad, & Schwartz, 2018; Newby et al., 2014; Hart 
et al., 2015; Brook et al., 2010; Correia et al., 2013). Little research is done to know whether 
keeping the annual PM2.5 concentrations below the USEPA standard would not have associated 
health effects. That knowledge would guide the advocacy about keeping that current standard 
or inform the need to lower the level to the less harmful. We hypothesized that the annual 
exposure to PM2.5 concentrations below the NAAQS was associated with the health effects such 
as hospital admissions or emergency department visits (EDV) or mortality for COPD, asthma, 
and myocardial infarction (MI).  
The objective of this study is to assess the association between the levels of ambient 
PM2.5 below NAAQS and COPD, asthma, MI as captured by hospital admissions; emergency 
department visits; and mortality. 
Methods 
Study design 
Our study covered 265 counties of 27 States of the United States (US). Data were 
selected for their recent availability on both exposure and outcome variables of interest. 
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Figure 3.1 Annual PM2.5 in US Counties in 2014  
(Source: CDC https://ephtracking.cdc.gov/DataExplorer/#/) 
We conducted a cross-sectional analysis using publicly available 2014 data from 265 
counties of 27 States of the United States. The observation unit of this study was a county. 
We used data from the year 2014 on annual particulate matter with diameter below 2.5µg 
(PM2.5) concentration, chronic obstructive pulmonary disease (COPD) hospitalizations, COPD 
mortality, COPD emergency department visits (EDV), asthma hospitalizations, asthma EDV, MI 
hospitalizations, and MI mortality from 265 counties of 27 States of the United States. Data 
were retrieved from the Environmental Public Health Tracking Network (EPHTN) of the Centers 
for Disease Control and Prevention (CDC) (CDC, 2018). The EPHTN database is fed by various 
information collected through different methods. State health departments provide data on 
hospitalizations and EDV, whereas mortality data are given by the National Vital Statistics 
System from the National Center for Health Statistics (NCHS). The annual PM2.5 concentration 
was measured through the US Environmental Protection Agency (USEPA) approved methods at 
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various sites in each State. Moreover, we used data on the 2014 county population obtained 
from the US Census Bureau database (US Census Bureau, 2015) and the 2011 average daily 
health index from CDC Wonder database (NLDAS, 2012). Finally, the counties in the study were 
both rural and urban and came from four US regions defined by the US Census Bureau, 
Midwest, Northeast, South, and West. 
Institutional Review Board Approval 
Our research was approved by the Institutional Review Board (IRB) of Georgia State 
University on October 25, 2018, under reference number 351592 and designated as “not 
human subjects research.”  
Exposure 
The independent or exposure variable was PM2.5. It represented the annual average 
ambient concentrations of PM2.5 in micrograms per cubic meter (µg/m3). The EPA extracted the 
raw air quality data from the Air Quality System (AQS) for the monitors designated as Federal 
Reference Methods or equivalent. Then, for each monitoring site, EPA retained the maximum 
concentration at the site for each monitored day. The annual average of PM2.5 is calculated 
using the site-level daily monitoring data for the monitors with completed quarterly and annual 
data. EPA calculated the quarterly average for each calendar quarter and then compute the 
annual average for each monitor with four valid quarters by averaging the quarterly averages. 
Outcomes 
There were seven dependent or outcome variables: COPD hospitalizations, COPD 
mortality, COPD EDV, asthma hospitalizations, asthma EDV, MI hospitalizations, and MI 
mortality.  
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The variable COPD EDV was the age–adjusted rate of emergency department visits 
among persons 25 and over for COPD per 10,000 population. That variable derived from the 
following measures: the numerator was the emergency department visits during a calendar 
year with COPD as the primary diagnosis and defined from the ninth revision of the International 
Classification of Diseases (ICD-9), the denominator was the midyear resident population 
estimates for state and by county, and the age–adjustment was done by the direct method to 
the year 2000 U.S. Standard Population. 
The variable COPD hospitalizations was the age–adjusted rate of hospitalization for 
COPD among persons 25 and over per 10,000 population. That variable was calculated from the 
following elements: the numerator was the resident hospitalizations during a calendar year 
with COPD as the primary diagnosis and defined from the ninth revision of the International 
Classification of Diseases (ICD-9), the denominator was the midyear resident population 
estimates, and the age–adjustment was done by the direct method to the year 2000 U.S. 
Standard Population. 
The variable COPD mortality was the annual age–adjusted death rates among persons 
25 and over per 100,000 population. That variable was calculated as the following: the 
numerator was the total number of deaths with COPD in the geographic region of interest, 
during a calendar year from the death certificate data, defined from the ninth revision of the 
International Classification of Diseases (ICD-9), the denominator was the midyear resident 
population estimates for state and by county from U.S. Census Populations With Bridged Race 
Categories, and the age–adjustment was done by the direct method to the year 2000 U.S. 
Standard Population. 
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The variable asthma hospitalizations was the age-adjusted rate of hospitalization for 
asthma per 10,000 population. It was calculated from the following elements: the numerator 
was the resident hospitalizations for asthma as the primary diagnosis and defined from the 
ninth revision of the International Classification of Diseases (ICD-9), the denominator was the 
midyear resident population, and the age-adjustment was done by the direct method to the 
year 2000 US standard population. 
The variable asthma EDV was the annual age-adjusted rate of emergency department 
visits for asthma per 10,000 population. That variable was calculated as follow: the numerator 
was the emergency department visits during a calendar year with asthma as the primary 
diagnosis and defined from the ninth revision of the International Classification of Diseases 
(ICD-9), the denominator was the midyear resident population, and the age-adjustment by the direct 
method to the Year 2000 US Standard population. 
The variable MI hospitalizations was the age-adjusted rate of hospitalization for MI 
among persons 35 and over per 10,000 population. It was calculated as following: the 
numerator was the resident hospitalizations for acute myocardial infarction as the primary 
diagnosis and defined from the ninth revision of the International Classification of Diseases 
(ICD-9), the denominator was the midyear resident population, and the age-adjustment was 
done by the direct method to the Year 2000 US Standard population. 
The variable MI mortality was the annual age-adjusted death rate among persons 35 
and over per 100,000 population. That variable was calculated as the following: the numerator 
was the total number of deaths with acute MI, in the geographic region of interest, during a 
calendar year from the death certificate data, the denominator is the total number of residents 
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at the midyear in the geographic region of interest, during a calendar year from the US Census, 
and the age-adjustment was done by the direct method to the Year 2000 US Standard 
population. 
Covariate  
The main covariate was the heat index. The heat index was the reported measures of 
the average daily maximum heat index of the year 2011. Heat Index data are available for days 
with temperatures at or above 80 degrees Fahrenheit or 26.7 degrees Celsius.  It was calculated 
from the ambient dry bulb temperature (in degrees Fahrenheit) and the relative humidity 
(integer percentage). With seasonal variability, there is evidence showing associations between 
meteorological factors such as ambient temperature and relative humidity and risk for 
respiratory diseases, and cardiovascular diseases (Qiu et al., 2013; Phung et al., 2016; Bunker et 
al., 2016; …).  As the temperature is a component of the heat index, we found it important to 
include heat index as the covariate for that association. 
The other variables of the study were the rurality and the US region of the counties as 
defined by the US Census Bureau. They were included in the analysis for the reason both the 
exposure and the outcomes may not be uniformly distributed into differently US regions. 
Statistical Analysis 
We have used the Statistical Analysis System SAS (SAS Institute Inc., Cary, NC, USA) 
software program version 9.4 for all data analyses. The excel data set was developed from the 
information taken from the databases and then imported into SAS. The missing values of the 
continuous variables were coded by a period (“.”) and are not taken into consideration for the 
analysis.  
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We used the Shapiro-Wilk test to assess for normality of the outcome variables. We 
considered the natural logarithm transformation of outcome variables when the normality 
assumptions were not met. Then, exponentiation is done for both the slopes and the 95% 
confidence interval (CI).  
We conducted univariate analyses using linear regression models to check the 
association between the exposure variable and each outcome variable. Moreover, multiple 
linear regression models were used for multivariate analyses to check for the association 
between PM2.5 and COPD hospitalizations, COPD mortality, COPD EDV, asthma hospitalizations, 
asthma EDV, MI hospitalizations, and MI mortality, controlling for the heat index.  
Additionally, we tested for significance to include the interaction term between PM2.5 
and heat index and used r-square and cp criteria to ensure the selection of the best-fitted 
model. The significance level, alpha, for the decision, was set at 0.05.  
Moreover, we checked for an association between heat index and PM2.5 to help 
determine the role played by that covariate in the relationship between PM2.5 and the 
outcomes.            
Finally, we performed a sensitivity analysis on multivariate analyses considering levels of 
annual PM2.5 concentrations below 11, below 10 and below 9 µg/m3 to determine the strength 
of association between each outcome and the annual PM2.5, controlling for heat index, at each 
level. 
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Results 
Basic characteristics of variables  
A total of 265 counties from the four US regions were included in the study; 86% of 
them were rural and 14% urban. The average annual PM2.5 was 8.53 (SD: 2.22). The average 
maximum heat index was 90.41 (SD: 3.81). The median age–adjusted rate of hospitalization for 
COPD among persons 25 and over per 10,000 population was 21.40 (IQR: 14.60). The median 
age–adjusted rate of emergency department visits for COPD among persons 25 and over per 
10,000 population was 63.20 (IQR: 41.85). The median age–adjusted death rates for COPD 
among persons 25 and over per 100,000 population was 61.70 (IQR: 23.50). The median age-
adjusted rate of hospitalization for asthma per 10,000 population was 8.60 (IQR: 5.80). The 
median age-adjusted rate of EDV for asthma per 10,000 population was 56.10 (IQR: 23.10). The 
median age-adjusted rate of hospitalization for MI among persons 35 and over per 10,000 
population was 27.80 (IQR: 8.70). The median age-adjusted rate of mortality for MI among 
persons 35 and over per 10,000 population was 51.80 (IQR: 21.70). 
Univariate and multivariate analyses for the US 
At levels below 12 µg/m3, a 1-unit increment in the annual PM2.5 concentrations was 
linked with an increase of 1.06 (95%CI: 1.02, 1.09)-unit in COPD hospitalizations, an increase of 
1.06 (95%CI: 1.03, 1.09)-unit in asthma hospitalizations, an increase of 1.04 (95%CI: 1.01, 1.08)-
unit in asthma EDV, an increase of 1.03 (95%CI: 1.01, 1.05)-unit in MI hospitalizations, and an 
increase of 1.04 (95%CI: 1.01, 1.07)-unit in MI mortality. Inversely, an increase in the annual 
PM2.5 concentrations was not associated with an increase in age-adjusted rate of COPD EDV and 
in age-adjusted rate of COPD mortality (respectively p=0.1317 and p=0.4941). 
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At levels below 12 µg/m3, controlling for heat index, a 1-unit increment in the annual 
PM2.5 concentrations was linked with an increase by 2.97 (95%CI: 1.32, 6.69)-unit in COPD 
hospitalizations a decrease of 0.95 (95%CI: 0.90, 0.99)-unit in COPD EDV, an increase of 2.75 
(95%CI: 1.21, 6.23)-unit in asthma hospitalizations, and an increase of 2.83 (95%CI: 1.34, 5.93)-
unit in asthma EDV.  
Heath index was associated with both PM2.5 (0.18, 95%CI: 0.13, 0.23) and each outcome 
[COPD hospitalizations (0.07, 95%CI: 0.06, 0.08), COPD EDV (0.07, 95%CI: 0.05, 0.09), COPD 
mortality (0.01, 95%CI: 0.01, 0.02), asthma hospitalizations (0.04, 95%CI: 0.02, 0.05), asthma 
EDV (0.03, 95%CI: 0.01, 0.04), MI hospitalizations (0.02, 95%CI: 0.01, 0.03), MI mortality (0.03, 
95%CI: 0.02, 0.04)]. 
Multivariate analyses by county rurality 
In urban counties, at the levels below 12 µg/m3, controlling for heat index, a 1-unit 
increase in the annual PM2.5 concentration was associated with an increase of 2.74 (95%CI: 
1.34, 5.64)-unit in COPD hospitalizations, a decrease by 0.29 (95%CI: 0.12, 0.73)-unit in COPD 
EDV, a decrease of 0.46 (95%CI: 0.28, 0.77)-unit in COPD mortality, an increase of 3.10 (95%CI: 
1.35, 7.10)-unit in asthma hospitalizations, an increase of 2.92 (95%CI: 1.28, 6.69)-unit in 
asthma EDV, and an increase of 1.03 (95%CI: 1.01, 1.06)-unit in MI mortality.  
In rural counties, at the levels below 12 µg/m3, controlling for heat index, a 1-unit 
increase in the annual PM2.5 concentrations was associated with any change in the outcomes 
COPD hospitalizations (7.10, 95%CI: 0.03, 1864.10)), COPD EDV (0.27, 95%CI: 0.00, 126.20), 
COPD mortality (1.27, 95%CI: 0.12, 14.07), asthma hospitalizations (1.77, 95%CI: 0.04, 75.19), 
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asthma EDV (1.82, 95%CI: 0.16, 20.29), MI. hospitalizations (0.94, 95%CI: 0.06, 15.03), and MI. 
mortality (0.99, 95%CI: 0.90, 1.09).  
Multivariate analyses by the US regions 
In the Midwest region, at the levels below 12 µg/m3, controlling for heat index, a 1-unit 
increase in the annual PM2.5 concentrations was associated with a decrease of 0.90 (95%CI: 
0.19, 0.99)-unit in heart attack mortality. 
In the Northeast region, at the levels below 12 µg/m3, controlling for heat index, a 1-unit 
increase in the annual PM2.5 concentrations was associated with a decrease of 0.08 (95%CI: 
0.01, 0.78)-unit in COPD hospitalizations, a decrease of 0.08 (95%CI: 0.01, 0.93)-unit in COPD 
mortality, a decrease of 0.11 (95%CI: 0.02, 0.73)-unit in MI. hospitalizations, and an increase of 
1.04 (95%CI: 1.00, 1.09)-unit in MI. mortality.  
In the South region, at the levels below 12 µg/m3, a 1-unit increase in the annual PM2.5 
concentrations was associated with an increase of 1.12 (95%CI: 1.05, 1.20)-unit in MI. mortality, 
controlling for heat index. 
In the West region, at the levels below 12 µg/m3, a 1-unit increase in the annual PM2.5 
concentrations was associated with an increase of 8.41 (95%CI: 1.65, 42.52) in COPD 
hospitalizations, controlling for heat index. 
Sensitivity analysis 
Sensitivity analysis revealed that for levels below 11 µg/m3 to below 9 µg/m3, 
controlling for heat index, a 1-unit increase in the concentration of the annual PM2.5 was 
strongly associated with an increase in COPD hospitalizations, an increase in asthma 
hospitalizations, and an increase in asthma EDV. A decrease in COPD EDV was seen for a 1-unit 
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increase in the concentration of the annual PM2.5 for levels below 9 µg/m3. A decrease in COPD 
mortality was observed for a 1-unit increase in the concentration of the annual PM2.5 for levels 
below 11 µg/m3 and below 9 µg/m3. No change was observed for MI hospitalizations and MI 
mortality when there was a 1-unit increase in the concentration of the annual PM2.5 for levels 
below 11 µg/m3 and below 9 µg/m3.  
Discussion 
This study assessed the association between the annual exposure to PM2.5 at levels 
below NAAQS standard of 12 µg/m3 and hospital admissions or EDV or mortality for COPD, 
asthma, and MI, controlling for heat index. Overall, we found that long-term exposure to PM2.5 
at levels below 12 µg/m3 was positively associated with COPD hospitalizations, asthma 
hospitalizations, asthma EDV, MI hospitalizations, and MI mortality. Furthermore, controlling 
for heat index, long-term exposure to PM2.5 at levels below 12 µg/m3 was positively associated 
with COPD hospitalizations, asthma hospitalizations, and asthma EDV. However, controlling for 
heat index, long-term exposure to PM2.5 at levels below 12 µg/m3 was negatively associated 
with COPD EDV. Various associations were observed for urban counties, whereas none was 
seen for rural counties. The results for rural counties may be explained by the lower mean 
concentration of PM2.5 observed in rural counties compared to urban one or the low number of 
rural counties covered in our study. Similarly, controlling for heat index, the types and strengths 
of associations between long-term exposure to PM2.5 at levels below 12 µg/m3 and the 
different outcomes were slightly different for each US region. Those differences may be 
partially explained by the differences in mean concentrations of PM2.5 and heat index in the 
regions; but also by the difference in the levels of other air pollutants and covariates not 
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covered in our study. Finally, some of the associations between long-term exposure to PM2.5 at 
levels below 12 µg/m3 and the different outcomes were observed even when the 
concentrations of the annual PM2.5 were lowered until the level below 9 µg/m3. The covariate 
heat index is a confounder for each of the associations between PM2.5 and the outcomes. 
Several studies have shown that long-term exposure to PM2.5 is associated with risk or 
mortality for COPD, asthma or MI. Morgan et al. (2003) have observed in their study, in Sydney 
metropolitan area, that exposure to low levels of PM2.5 was associated with all-cause mortality, 
including all cardiovascular mortality and all respiratory mortality. Moreover, in the Harvard Six 
Cities Study, Schwartz et al. (1996) have observed, when controlling for weather, that a 
10 µg/m3 change in PM2.5 was strongly associated with 1.5% (95%CI: 1.1, 1.9) increase in total 
daily mortality but when they controlled for weather, they found the association at 1.3% 
(95%CI: 1.0, 1.7). Their results are similar to ours for MI. in the non-adjusted analysis [3% 
(95%CI: 1.0, 5.0)] whereas they contrast with what we have observed in the adjusted models 
where there was no association. The differences observed may be explained by the use of 
limited number of covariates in our study. In a cohort of 189,793 men of 40 years old and older 
in China, Yin et al. (2017) have observed that long-term exposure to PM2.5 was linked to COPD 
mortality (HR=1.12, 95%CI: 1.10, 1.13). Their results contrast with what we have obtained for 
COPD mortality. That difference may be explained by the mean PM2.5 concentration in their 
study that was higher compared to ours. Conversely, Atkinson et al. (2015) have found in their 
cohort of 812 063 patients in the UK a piece of inconclusive evidence for the associations 
between long-term PM2.5 and COPD (OR of 1.14, 95% CI: 0.96, 1.36). That result may indicate a 
lack of statistical power as they used COPD admissions that may unlikely reflect the burden of 
24 
 
the disease in the population. Only COPD patients with severe or poorly controlled symptoms 
would be admitted in hospitals. For asthma, Gehring et al. (2010) have conducted a study in 
children and found that PM2.5 levels were associated with a significant rise in the incidence of 
asthma (OR,1.28, 95%CI: 1.10, 1.49), prevalence of asthma (OR, 1.26; 95% CI: 1.04, 1.51), and 
prevalence of asthma symptoms (OR, 1.15; 95% CI: 1.02, 1.28). Moreover, Nishimura et al. 
(2013) have determined, in their retrospective case-control in children in the US, that first year 
of life exposure to PM2.5 was associated with asthma (OR,1.2, 95%CI: 0.6, 2.3). Finally, the US 
cohort study conducted on 50,884 women showed that exposure to PM2.5 is associated with a 
higher incidence of asthma (Young et al., 2014). The association between long-term exposure 
to PM2.5 has also been described in the literature. For instance, the European expert position 
paper (Newby et al., 2014) and the AHA (Brook et al., 2010) have concluded on the evidence 
that long-term exposure to PM2.5 is associated with various cardiovascular outcomes, including 
myocardial infraction. 
Our results seem to support the existing knowledge on the association between long-
term exposure to PM2.5 and COPD, asthma, and MI. Moreover, that association was still 
observed when we controlled for heat index. We distinguished our findings from previous 
research by limiting the exposure to the annual PM2.5 concentration at levels 12.0 µg/m3. Our 
results went beyond the existing literature by indicating that, at the population level, 
controlling for heat index or not, long-term exposure to PM2.5 at levels below 12.0 µg/m3 may 
still be harmful to public health. When we controlled for heat index, the strength of the 
association was higher at lower PM2.5 concentrations for COPD hospitalizations, asthma 
hospitalizations, and asthma EDV. 
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This study was not exempt from limitations. Our analysis performed in only one-year 
data could not assess the magnitude of how the change in the concentrations of PM2.5 over 
time may affect the outcomes. Also, PM2.5 concentrations and heat index may have seasonal 
variations that were not captured in our study. Longitudinal studies covering many years and 
including seasonal information would better capture precise association. Also, the average daily 
maximum heat index used as covariate did not consider days with low heat index that may 
influence differently the association. Moreover, there may be a possibility for misclassification 
of fine PM with other PM or confounding with other pollutants and covariates not included in 
our study.   Furthermore, there might be reasons that influenced some counties to monitor the 
pollutant. Additionally, COPD is a disease that affects in different way children and adults; the 
data we used for COPD cover only adult populations above 25 years old. Therefore, the effect 
size we observed for that outcome may not reflect the picture in the general population. Finally 
our research, may suffer fallacies as all ecological studies if we try to link the observed 
associations at the population level with any individual subject. 
Our findings suggest that long-term exposure to PM2.5 at levels below the current 
NAAQS of 12.0 µg/m3 was associated with adverse health effects, controlling or not for heat 
index. Based on our existing NAAQS, there was 197% excess risk for COPD hospitalizations, 
175% excess risk for asthma hospitalizations, 183% excess risk for asthma EDV, and 5% lower 
risk for COPD EDV. Additional studies are indicated to better understand those relationships 
and to support health risk reduction efforts. 
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TABLES AND FIGURES – RESULTS 
 
                               Table 3.1 Basic characteristics of variables 
Variable N Mean Std Dev Median IQR 
Heath index 
PM2.5 
COPD H.a 
Asthma H.c 
MI H.d 
COPD M.b  
MI M.e 
COPD E.D.V.a 
Asthma E.D.V.c 
 
265 
265 
257 
262 
265 
265 
265 
188 
195 
 
90.41 
8.53 
24.56 
9.83 
29.79 
63.89 
58.83 
75.09 
57.05 
 
3.81 
2.22 
17.53 
4.83 
8.34 
19.12 
25.11 
54.66 
21.90 
 
91.00 
8.60 
21.40 
8.60 
27.80 
61.70 
51.80 
63.20 
56.10 
 
5.00 
2.40 
14.60 
5.80 
8.70 
23.50 
21.70 
41.85 
23.10 
 
a Age-adjusted rate of hospitalizations (COPD H) and emergency department visits (COPD EDV) for COPD for persons 25 and over per 10,000 
population  
b Age-adjusted death rate from COPD among persons 25 and over per 100,000 population (COPD Mortality) 
c Age-adjusted rate of hospitalizations (Asthma H) and emergency department visits (Asthma EDV) for asthma per 10,000 population 
d Age-adjusted rate of hospitalizations for myocardial infarction (MI. H.) among persons 35 and over per 10,000 population  
e Age-adjusted rate of death from myocardial infarction among persons 35 and older per 100,000 population (MI. Mortality) 
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Table 3.2 Basic characteristics of variables per rurality  
Variable N 
Urban   Rural 
Mean 
Urban    Rural 
Std Dev 
Urban   Rural 
Median 
Urban   Rural 
Heath index 
PM2.5 
COPD H.a 
Asthma H.c 
MI H.d 
COPD M.b  
MI M.e 
COPD E.D.V.a 
Asthma E.D.V.c 
 
228      37 
228      37 
221     36 
225     37 
228     37 
228     37 
228     37 
159     29 
165     30 
 
90.53     89.65 
8.66     7.70 
22.73    35.75 
10.20     7.61 
29.04     34.46 
61.35     79.55 
55.83     77.00 
66.24    123.61 
57.84     52.76 
 
3.77     4.04 
2.22     2.07 
10.09    38.16 
4.93     3.50 
7.62     10.88 
16.57     25.62 
19.99     41.36 
36.94     96.79 
23.19     12.03 
 
91.00     90.00 
8.70      8.00 
20.90     25.10 
9.10     6.50 
27.40     30.00 
60.35     71.00 
50.75     60.20 
57.60     84.80 
56.90     51.40 
 
a Age-adjusted rate of hospitalizations (COPD H) and emergency department visits (COPD EDV) for COPD for persons 25 and over per 10,000 
population  
b Age-adjusted death rate from COPD among persons 25 and over per 100,000 population (COPD Mortality) 
c Age-adjusted rate of hospitalizations (Asthma H) and emergency department visits (Asthma EDV) for asthma per 10,000 population 
d Age-adjusted rate of hospitalizations for myocardial infarction (MI. H.) among persons 35 and over per 10,000 population  
e Age-adjusted rate of death from myocardial infarction among persons 35 and older per 100,000 population (MI. Mortality) 
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Table 3.3 Basic characteristics of variables per region  
Variable N 
MW⁺  NE⁺⁺ S⁺⁺⁺W⁺⁺⁺⁺  
Mean 
MW   NE   S   W 
Std Dev 
MW   NE   S  W 
Median 
MW   NE   S   W 
Heath index 
PM2.5 
COPD H.a 
Asthma H.c 
MI H.d 
COPD M.b  
MI M.e 
COPD E.D.V.a 
Asthma E.D.V.c 
 
60   71   68   66 
60   71   68   66 
53   70   68   66 
60   69   67   66 
60   71   68   66 
60   71   68   66 
60   71   68   66 
37   53   45   53 
43   54   45   53 
 
93.0   89.2   93.6   86.1 
8.8      8.1      8.7     8.6 
22.7   24.0   37.5   13.4 
8.48    12.6    11.2    6.8 
30.1    29.8    35.5    23.7 
66.4    52.0    75.8    62.2 
59.3    54.4    74.4    47.1 
64.6    61.8    127.8    50.9 
46.7    68.3    68.7    44.2 
 
2.3    1.3    1.9    3.5 
1.3    1.9    1.5    3.5 
8.7    5.2    27.7    5.1 
4.3    6.3    3.4    1.9 
7.5    5.9    10.1    4.0 
11.3    13.0    25.6    14.1 
24.5    12.9    35.5    11.0 
32.0    28.8   2.2    21.4 
16.0    25.1    17.6    13.2 
 
92.0    89.0    94.0   85.5 
8.8    8.2    9.0     7.7 
21.2    23.3    33.4   12.7 
7.0    11.5    11.5    6.6 
27.5    28.8    32.7   23.6 
64.7    50.6    75.1   59.7 
54.9    50.7    63.2   45.0 
57.6    56.9    95.4   48.6 
46.6    63.0    65.4   43.4 
 
a Age-adjusted rate of hospitalizations (COPD H) and emergency department visits (COPD EDV) for COPD for persons 25 and over per 10,000 
population  
b Age-adjusted death rate from COPD among persons 25 and over per 100,000 population (COPD Mortality) 
c Age-adjusted rate of hospitalizations (Asthma H) and emergency department visits (Asthma EDV) for asthma per 10,000 population 
d Age-adjusted rate of hospitalizations for myocardial infarction (MI. H.) among persons 35 and over per 10,000 population  
e Age-adjusted rate of death from myocardial infarction among persons 35 and older per 100,000 population (MI. Mortality) 
MW⁺: US Midwest region 
NE⁺⁺: US Northeast region 
S⁺⁺⁺: US South region 
W⁺⁺⁺⁺: US West region 
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Table 3.4 Univariate analyses for the association between PM2.5 and outcomes variables 
(PM2.5<12 µg/m3) 
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 245 1.06 (1.02, 1.09) 0.0040 
COPD EDVb 177 1.04 (0.99, 1.09) 0.1317 
COPD Mortality 253 1.01 (0.99, 1.03) 0.4941 
Asthma Hospitalizations 250 1.06 (1.03, 1.09) 0.0007 
Asthma EDVb 184 1.04 (1.01, 1.08) 0.0065 
MIc Hospitalizations 253 1.03 (1.01, 1.05) 0.0005 
MIc Mortality 253 1.04 (1.01, 1.07) 0.0051 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
 
 
Table 3.5 Multivariate analyses for the association between PM2.5 and outcomes variables 
(PM2.5<12 µg/m3) 
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 245 2.97 (1.32, 6.69) 0.0085 
COPD EDV** 177 0.95 (0.90, 0.99) 0.0455 
COPD EDVb 253 0.99 (0.97, 1.01) 0.4168 
COPD Mortality 250 2.75 (1.21, 6.23) 0.0155 
Asthma Hospitalizations 184 2.83 (1.34, 5.93) 0.0070 
Asthma EDVb 253 1.01 (0.99, 1.03) 0.2092 
MIc Hospitalizations 253 1.01 (0.98, 1.04) 0.3978 
MIc Mortality     
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
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Table 3.6 Multivariate analyses for the association between PM2.5 and outcomes variables for 
urban counties (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 210 2.74                           (1.34, 5.64)     0.0062 
COPD EDVb 149 0.29   (0.12, 0.73) 0.0090 
COPD Mortality 217 0.46 (0.28, 0.77)   0.0034 
Asthma Hospitalizations 214 3.10 (1.35, 7.10) 0.0081 
Asthma EDVb 155 2.92 (1.28, 6.69) 0.0109 
MIc Hospitalizations 217 1.42 (0.93, 2.18) 0.1030 
MIc Mortality 217 1.03 (1.01, 1.06) 0.0360 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
 
 
Table 3.7 Multivariate analyses for the association between PM2.5 and outcomes variables for 
rural counties (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 35 7.10            (0.03, 1864.1)     0.4788 
COPD EDVb 28 0.27   (0.00, 126.2) 0.6617 
COPD Mortality 36 1.27 (0.12, 14.07) 0.8322 
Asthma Hospitalizations 36 1.77 (0.04, 75.19) 0.7580 
Asthma EDVb 29 1.82 (0.16, 20.29) 0.6166 
MIc Hospitalizations 36 0.94 (0.06, 15.03) 0.9651 
MIc Mortality 36 0.99 (0.90, 1.09) 0.8654 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
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Table 3.8 Multivariate analyses for the association between PM2.5 and outcomes variables for 
the US Midwest region (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 53 0.25 (0.02, 3.90)    0.3135 
COPD EDVb 37 0.09 (0.00, 1.84)   0.1143 
COPD Mortality 60 0.66 (0.26, 1.72) 0.3926 
Asthma Hospitalizations 60 0.33 (0.02, 6.69) 0.4693 
Asthma EDVb 43 0.15 (0.01, 1.70) 0.1208 
MIc Hospitalizations 60 0.29 (0.06, 1.46) 0.1305 
MIc Mortality 60 0.90 (0.19, 0.99) 0.0272 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
 
 
Table 3.9 Multivariate analyses for the association between PM2.5 and outcomes variables for 
the US Northeast region (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 69 0.08         (0.01, 0.78)   0.0300 
COPD EDVb 53 1.60   (-2.62, 94.63)   0.8191 
COPD Mortality 70 0.08   (0.01, 0.93) 0.0445 
Asthma Hospitalizations 68 6.05 (0.07, 513.86) 0.4204 
Asthma EDVb 54 0.93 (0.02, 54.05) 0.9725 
MIc Hospitalizations 70 0.11 (0.02, 0.73) 0.0229 
MIc Mortality 70 1.04 (1.00, 1.09) 0.0465 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
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Table 3.10 Multivariate analyses for the association between PM2.5 and outcomes variables for 
the US South region (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 67 0.17  (0.00, 39.65)   0.5154 
COPD EDVb 44 0.02   (0.00, 584.06) 0.4608 
COPD Mortality 67 2.64   (0.06, 127.74) 0.6178 
Asthma Hospitalizations 66 0.25 (0.01, 9.30) 0.4491 
Asthma EDVb 44 31.19 (0.23, 4315.6) 0.1659 
MIc Hospitalizations 67 1.80 (0.08, 40.04) 0.7039 
MIc Mortality 67 1.12 (1.05, 1.20) 0.0010 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
 
 
Table 3.11 Multivariate analyses for the association between PM2.5 and outcomes variables for 
the US West region (PM2.5<12 µg/m3)  
Outcome variables N Effect sizea 95%CI P-value 
COPD Hospitalizations 56 8.41          (1.65, 42.52) 0.0114 
COPD EDVb 43 2.64    (0.17, 40.85) 0.4781 
COPD Mortality 56 2.29 (0.11, 6.69) 0.1294 
Asthma Hospitalizations 56 2.25 (0.77, 6.49) 0.1334 
Asthma EDVb 44 2.56 (0.54, 12.18) 0.2305 
MIc Hospitalizations 56 1.88   (0.88, 3.97) 0.1020 
MIc Mortality 56 1.00 (0.97, 1.04) 0.9052 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration    
b EVD: emergency department visits 
c MI: myocardial infarction  
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Table 3.12 Sensitivity analysis table  
Outcome variables Levels of 
PM2.5 
N Effect sizea 95%CI P-value 
 
COPD Hospitalizationsb 
<11 236 2.86 1.19 6.90 0.0194 
<10 210 4.86 1.58 14.96 0.006 
<9 151 9.15 1.96 42.84 0.0052 
 
COPD EDVb 
<11 173 0.95 0.90 1.00 0.0621 
<10 156 0.96 0.90 1.02 0.1793 
<9 123 0.90 0.84 0.97 0.0066 
 
COPD Mortalityc 
<11 244 0.48 0.27 0.84 0.0113 
<10 217 1.00 0.98 1.03 0.8107 
<9 155 0.36 0.14 0.95 0.0382 
 
Asthma 
Hospitalizationsd 
<11 241 2.93 1.20 7.12 0.018 
<10 215 4.35 1.54 12.28 0.0057 
<9 154 13.73 3.39 55.52 0.0003 
 
Asthma EDVd 
<11 180 3.71 1.64 8.41 0.0018 
<10 163 6.39 2.38 17.13 0.0003 
<9 127 8.48 2.25 31.99 0.0018 
 
MI. Hospitalizationse 
<11 244 1.01 0.99 1.04 0.2857 
<10 217 1.02 0.99 1.04 0.2305 
<9 155 1.01 0.98 1.04 0.6402 
 
MI. Mortalityf 
<11 244 1.01 0.98 1.04 0.4666 
<10 217 1.01 0.98 1.05 0.5385 
<9 155 1.01 0.96 1.06 0.7337 
a Unit change in outcome for 1-unit increase in annual PM2.5 concentration, controlling for heat index    
b Age-adjusted rate of hospitalizations (COPD H) and emergency department visits (COPD EDV) for COPD for persons 25 and over per 10,000 
population  
c Age-adjusted death rate from COPD among persons 25 and over per 100,000 population (COPD Mortality) 
d Age-adjusted rate of hospitalizations (Asthma H) and emergency department visits (Asthma EDV) for asthma per 10,000 population 
e Age-adjusted rate of hospitalizations for myocardial infarction (MI. H.) among persons 35 and over per 10,000 population  
f Age-adjusted rate of death from myocardial infarction among persons 35 and older per 100,000 population (MI. Mortality) 
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          Figure 3.2. US counties covered in the study by US Regions  
 
 
 
 
         Figure 3.3 US counties covered in the study by rurality 
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